TREM1 and hypertriglyceridemia: showed that those with several cardiometabolic risk factors (hypertension, hypertriglyceridemia, low HDL, or abdominal obesity) had higher serum concentrations of sTREM-1 (18), a biomarker of the TREM-1 pathway activation (24), and suggested that the follow-up of this marker may alert on the development of a future metabolic syndrome.